The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Hepatitis C Triple Therapy Response Predicted in Four Weeks

Back to News Homepage

Next

Biotica Seeking Patent for New Class of Hepatitis C Drug

Encouraging Interim Trial Results for Hep C Non-Responders

October 25, 2011

Print this page

After just three months of a Phase 2b study, Setrobuvir with pegylated interferon and ribavirin led to undetectable viral levels in over three quarters of previous Hepatitis C treatment non-responders.

Anadys achieves positive interim results in ongoing phase 2b hepatitis C study

October 13, 2011

by Olivia D’Orazio

Anadys Pharmaceuticals (NASDAQ:ANDS) announced Thursday positive interim results in its ongoing phase 2b study of setrobuvir, in combination with pegylated interferon and ribavirin (P/R), in patients with the hepatitis C virus.

The study dosed 283 patients suffering from hepatitis C, who were either treatment naive, or experienced either a relapse or no response to previous P/R treatments.

Continue reading this entire article:
http://www.proactiveinvestors.com/companies/news/19618/anadys-achieves-positive-interim-results-in-ongoing-phase-2b-hepatitis-c-study-19618.html

No Comments - be the first!
Share
Share

Previous

Hepatitis C Triple Therapy Response Predicted in Four Weeks

Back to News Homepage

Next

Biotica Seeking Patent for New Class of Hepatitis C Drug

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.